gmx1777

Small moleculeexperimental

Clinical trial activity

1 trials · 1 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0

Earliest trial started Mar 1, 2007 (NCT00457574)

Timeline

2000s

  1. Jan 1, 2007

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

COCCOCCOCCOCCOC(=O)OC[n+]1ccc(N/C(=N/C#N)NCCCCCCOc2ccc(Cl)cc2)cc1.[Cl-]
Mol. weight
672.61 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Prodrug

Sources

Also known as

  • 1-(2-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)ethoxycarbonyloxymethyl)-4-(n'-cyano-n''-(6-(4-chlorophenoxy)hexyl)-n-guanidino)pyridinium
  • 1-(2-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)ethoxycarbonyloxymethyl)-4-(n'-cyano-n''-(6-(4-chlorophenoxy)hexyl)-n-guanidino)pyridinium chloride
  • eb1627
  • eb 1627
  • eb-1627
  • eb-1627
  • eb-1627
  • gmx1777
  • gmx1777
  • gmx1777
  • gmx1777
  • gmx1777
  • gmx 1777
  • gmx-1777
  • teglarinad chloride
  • teglarinad chloride

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT00457574Phase 1Mar 1, 2007Gemin X
Showing 1 of 1 trials
Page 1 / 1

Organizations

Research & Development (1)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Gemin XFor profit1112007
1 organizations
Page 1 / 1